172 related articles for article (PubMed ID: 26536105)
61. Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
Rodriguez CA; Agudelo M; Aguilar YA; Zuluaga AF; Vesga O
PLoS One; 2016; 11(5):e0155806. PubMed ID: 27191163
[TBL] [Abstract][Full Text] [Related]
62. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants.
Wade KC; Benjamin DK; Kaufman DA; Ward RM; Smith PB; Jayaraman B; Adamson PC; Gastonguay MR; Barrett JS
Pediatr Infect Dis J; 2009 Aug; 28(8):717-23. PubMed ID: 19593252
[TBL] [Abstract][Full Text] [Related]
63. Impact on resistance of the use of therapeutically equivalent generics: the case of ciprofloxacin.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Antimicrob Agents Chemother; 2015 Jan; 59(1):53-8. PubMed ID: 25313208
[TBL] [Abstract][Full Text] [Related]
64. Fluconazole, with or without dexamethasone for experimental cryptococcosis: impact of treatment timing.
Lortholary O; Nicolas M; Soreda S; Improvisi L; Ronin O; Petitjean O; Dupont B; Tod M; Dromer F
J Antimicrob Chemother; 1999 Jun; 43(6):817-24. PubMed ID: 10404321
[TBL] [Abstract][Full Text] [Related]
65. Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis.
Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Patterson TF
Clin Microbiol Infect; 2012 Feb; 18(2):E20-3. PubMed ID: 22128831
[TBL] [Abstract][Full Text] [Related]
66. In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.
Andes D; Marchillo K; Lowther J; Bryskier A; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Apr; 47(4):1187-92. PubMed ID: 12654645
[TBL] [Abstract][Full Text] [Related]
67. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis.
Martinez A; Aviles P; Jimenez E; Caballero J; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 Dec; 44(12):3389-94. PubMed ID: 11083645
[TBL] [Abstract][Full Text] [Related]
68. Biodistribution of free and encapsulated
de Assis DN; Araújo RS; Fuscaldi LL; Fernandes SOA; Mosqueira VCF; Cardoso VN
Biomed Pharmacother; 2018 Mar; 99():438-444. PubMed ID: 29665644
[TBL] [Abstract][Full Text] [Related]
69. Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection.
Wang L; Wang C; Mei H; Shen Y; Lv G; Zeng R; Zhan P; Li D; Liu W
Mycopathologia; 2016 Feb; 181(1-2):29-39. PubMed ID: 26404163
[TBL] [Abstract][Full Text] [Related]
70. Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.
Kullberg BJ; van 't Wout JW; Poell RJ; van Furth R
Antimicrob Agents Chemother; 1992 Jun; 36(6):1225-9. PubMed ID: 1416821
[TBL] [Abstract][Full Text] [Related]
71. Pharmacokinetics of fluconazole and ganciclovir as combination antimicrobial chemotherapy on ECMO: a case report.
Dhanani JA; Lipman J; Pincus J; Townsend S; Livermore A; Wallis SC; Abdul-Aziz MH; Roberts JA
Int J Antimicrob Agents; 2021 Nov; 58(5):106431. PubMed ID: 34520832
[TBL] [Abstract][Full Text] [Related]
72. Fluconazole loading dose pharmacokinetics and safety in infants.
Piper L; Smith PB; Hornik CP; Cheifetz IM; Barrett JS; Moorthy G; Hope WW; Wade KC; Cohen-Wolkowiez M; Benjamin DK
Pediatr Infect Dis J; 2011 May; 30(5):375-8. PubMed ID: 21085048
[TBL] [Abstract][Full Text] [Related]
73. [Effect of qishen huoxue granule combined with fluconazole on survival rate of mice with systemic C. albaicans infection].
Li SR; Wang H; Zhang SW
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2008 Sep; 28(9):832-4. PubMed ID: 19065900
[TBL] [Abstract][Full Text] [Related]
74. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.
Louie A; Liu QF; Drusano GL; Liu W; Mayers M; Anaissie E; Miller MH
Antimicrob Agents Chemother; 1998 Jun; 42(6):1512-4. PubMed ID: 9624506
[TBL] [Abstract][Full Text] [Related]
75. [Therapeutic equivalence evaluated by in vitro studies of multisource pharmaceutical products: case studies of amoxicillin, doxycycline and fluconazole in Lima, Peru].
Grande-Ortiz M; Taipe-Cadenillas S; Villodas-Saldaña C; Rodríguez-Calzado J; Moreno-Exebio L
Rev Peru Med Exp Salud Publica; 2019; 36(1):74-80. PubMed ID: 31116343
[TBL] [Abstract][Full Text] [Related]
76. Pharmacokinetics of oral fluconazole when used for prophylaxis in bone marrow transplant recipients.
El-Yazigi A; Ellis M; Ernst P; Spence D; Hussain R; Baillie FJ
Antimicrob Agents Chemother; 1997 May; 41(5):914-7. PubMed ID: 9145843
[TBL] [Abstract][Full Text] [Related]
77. Variability of plasma fluconazole levels in patients with hematologic malignancy.
Ellis ME; Spence D; Ernst P; Greer W
Clin Infect Dis; 1997 Jan; 24(1):86-7. PubMed ID: 8994774
[No Abstract] [Full Text] [Related]
78. Pharmacokinetics of fluconazole in children requiring peritoneal dialysis.
Wong SF; Leung MP; Chan MY
Clin Ther; 1997; 19(5):1039-47. PubMed ID: 9385491
[TBL] [Abstract][Full Text] [Related]
79. Application of microbiological assay to determine pharmaceutical equivalence of generic intravenous antibiotics.
Zuluaga AF; Agudelo M; Rodriguez CA; Vesga O
BMC Clin Pharmacol; 2009 Jan; 9():1. PubMed ID: 19149891
[TBL] [Abstract][Full Text] [Related]
80. Fluconazole pharmacokinetics and safety in premature infants.
Turner K; Manzoni P; Benjamin DK; Cohen-Wolkowiez M; Smith PB; Laughon MM
Curr Med Chem; 2012; 19(27):4617-20. PubMed ID: 22876898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
